OMR

Order-made Medical Research Inc.

Make the impossible possible for Therapeutic Antibody

About Us

Order-made Medical Research Inc. (OMR) is a biotech company promoting technology development that revolutionize therapeutic antibodies.

 

We have made it possible to generate prominent antibodies against multi-transmembrane target molecules that have been difficult to create and have succeeded in expanding the number of target molecules extremely for therapeutic antibodies. Furthermore, as a further application development, we are challenging to create innovative therapeutic antibodies targeted intracellular molecules and disease-specific immunogenicity changes that have been difficult to target antibodies.
 

We will pursue business to explore target molecules for therapeutic antibodies and generate them to out-license them to pharmaceuticals and biotech companies at the early stages of R&D.

 

新型コロナワクチン抗体検査のご案内

​新型コロナのワクチン接種による抗体量の変化を当社抗体検査により数値で確認できます。

​当社の抗体検査については、こちらもご覧ください。

※年内の結果報告書をご希望の方は、検体を当社最終12月22日(水)着でお送りください。
​それ以降の場合は、1月5日以降当社着となるようお送りください。

当社では、新型コロナウイルスワクチン接種による抗体量の変化を数値で確認できる抗体検査をご提供しております。

ご照会、お申込みは下記メールアドレスにご連絡をお願いいたします。当社から詳細についてご連絡させていただきます。

(本サービスの受付窓口は下記メールアドレスのみとさせていただいております。)​

​ご照会・お申込み窓口  :  kotai-kensa@omr.co.jp

News

2021/12/03

OMRロゴ.tif

新型コロナウイルス迅速抗体検査キット 販売開始

2021/11/08

OMRロゴ.tif

​茨城県つくば市につくば研究所を開設しました

2021/09/10

OMRロゴ.tif

​メディア説明会において、新型コロナウイルス感染症の医薬品として実用化を目指す『murak抗体』を紹介しました

2021/03/18

アルフレッサファーマロゴ2.jpg

​当社、アルフレッサ ファーマ社、DDサプライ社の3社で共同開発した新型コロナウイルス抗原迅速検査キット「アルソニック®  COVID-19 Ag」がアルフレッサ ファーマ社より販売開始

2020/10/20

ユーグレナ、リバネス_ロゴ.png

​当社、ユーグレナ社、リバネス社の3社で共同開発の新型コロナウイルス(SARS-CoV-2)抗体検査サービス、ユーグレナ社より医療機関向け提供開始

2020/08/26

OMRロゴ.tif

OMR had a press conference with regard to the release plan of a COVID-19 quantitative antibody testing system

2020/08/18

ユーグレナ、リバネス_ロゴ.png

OMR, Euglena, and Leave a Nest produced a standard antibody against the novel coronavirus (SARS-CoV-2) and confirmed the effect in the antibody test system under joint development

2020/07/06

ユーグレナ、リバネス_ロゴ.png

OMR, Euglena and Leave a Nest developed and verified an antibody test system for the novel coronavirus disease (COVID-19)

2017/12/13

675c5ae6b0bce07214fe716f2018384d.w400.h4

OMR Inc. has executed a Joint Research Agreement with Mitsubishi Tanabe Pharma on therapeutic antibodies for neurodegenerative diseases treatment including ALS.

2017/04/17

rtf_logo.png

OMR Inc. raised 300 million yen from Real Tech Fund.

 
 

 Our Technology 

Proprietary innovative antibody 
generating technology

We have established " LIMAXYS ™ ", an innovative antibody generating technology using metastatic cancer cell properties and made it possible to generate prominent antibodies against multi-transmembrane target molecules that have been difficult to create. This makes it possible to generate approximately 5,600 antibodies for all of membrane proteins theoretically.
 

Furthermore, we are working on to establish " INTAB ™ " internalization antibodies technologies targeting intracellular molecules, and " MUTAB ™ " selective antibody technologies recognizing disease specific immunogenicity changes associated with genetic mutations,  post-translational modifications and others. 
 

By applying various modalities (new therapeutic approach) with diversified partners, it makes possible to develop and provide therapeutic antibodies for difficult cancer types to treat, which showing multiple phenotypes, including drug resistance, immunological escaping and cancer stem cells,  and for refractory autoimmune diseases, neurodegenerative diseases and so on, that is expected to cause a substantial paradigm shift in future medical care.

Antibody Engineering

スクリーンショット 2018-10-13 23.16.47.png

LIMAXYS™️

Immunization by target molecule expressed metastatic tumor cell (genetically modified) transplantation

Extra Cellular Domain Antibody

Target molecules and potential Applications (modalities)

Trans membrane molecules

  • Agonistic antibodies

  • Cell-functional modified antibodies

  • Immuno-redirected Bi-Specific Antibodies

Bioinformatics

スクリーンショット 2018-10-13 23.16.51.png

INTAB™️

Immunization through epitope prediction via amino acid sequence and 3D structure

Internalization antibody

Target molecules and potential Applications (modalities)

Intracellular molecules

  • Payload Conjugated Antibodies:

    • ASO, siRNA, miRNA

    • Radio Active

    • Drug

  • Drug Delivery System

  • Intracellular multi-Specific Antibodies

Immuno-Genomics

スクリーンショット 2018-10-13 23.16.53.png

MUTAB™️

Immunization with targeting disease specific immunogenicity change

Disease Specified Selective Antibody

Target molecules and potential Applications (modalities)

Genetic mutation and immunogenicity

  • Hi Affinity and Tissue - Selectivity

  • ADCC/CDC Antibodies

  • CAR-T, TCR-T(MHC-Ag CAR-T)

 

Introduction of Founder

111.jpg

Yasufumi Murakami

​President and CEO

Dr. Murakami is a founder and CEO of OMR. Research Fellow at Alberta Einstein Medical University, Immunology, Sloan-Kettering Commemorative Cancer Research Center, Molecular Biology and Virology Division. After engaging in research on antibody and genomic biology at RIKEN, he became professor of the Department of Biological Engineering at Tokyo University of Science and also served as a visiting professor at Tottori University, founded OMR in 2012. Graduated doctoral course at University of Tokyo (Pharmaceutical Science). Specialty fields are therapeutic antibody, genomic biology, genetic engineering.

 

Access

Order-made Medical Research, Inc.

5-4-19 Kashiwanoha, Kashiwa-shi, Chiba 277 - 0882

Tokyo University Kashiwa Venture Plaza

In case of train

  1. Exit the Tsukuba Express Line Kashiwahaha Campus Station, about 10 minutes by bus to the National Cancer Research Center East Hospital

  2. Get off at the Cancer Research Center East Hospital and walk 3 minutes on foot

 

In case of car

  1. Approximately 2 km from Joban Express Kashiwa Interchange

  2. Head national highway 16 south in the direction of Kashiwa, turn right at intersection at the entrance of industrial park, turn right at the intersection of family mart

  3. Todai Kashiwa Venture Plaza (with a parking lot for visitors) on the left side

つくば研究所

〒300-2635 茨城県つくば市東光台五丁目5-4

電車の場合

   つくばエクスプレス線『研究学園』駅北口を出て、タクシーで約7分

自動車の場合

  1. 常磐高速谷田部インターチェンジからつくば方面に約8 km​                                             圏央道よりお越しの場合は、つくば中央インターチェンジから学園都市方面に約4 km

  2. 面野井台の交差点を東光台研究団地方面に進み、ZOZOBASEつくば1の手前を左折

  3. 200 m ほど進み、左手にある区画の左奥が当社つくば研究所

 

Contact

Inquiries about our technology and products are accepted here. Please contact us by telephone, fax, or contact form below. We will reply from our person in charge.

In case

TEL: 04 - 7157 - 4530 (weekdays 10: 00 ~ 17: 00) 
FAX: 04 - 7157 - 4643

メッセージを送信しました